Cargando…
Ganoderma: A Cancer Immunotherapy Review
Ganoderma is a significant source of natural fungal medicines and has been used for the treatment of various diseases for many years. However, the use of Ganoderma in cancer immunotherapy is poorly elucidated. In this study, we have analyzed 2,398 English-language papers and 6,968 Chinese-language p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209820/ https://www.ncbi.nlm.nih.gov/pubmed/30410443 http://dx.doi.org/10.3389/fphar.2018.01217 |
_version_ | 1783366977095467008 |
---|---|
author | Cao, Yu Xu, Xiaowei Liu, Shujing Huang, Linfang Gu, Jian |
author_facet | Cao, Yu Xu, Xiaowei Liu, Shujing Huang, Linfang Gu, Jian |
author_sort | Cao, Yu |
collection | PubMed |
description | Ganoderma is a significant source of natural fungal medicines and has been used for the treatment of various diseases for many years. However, the use of Ganoderma in cancer immunotherapy is poorly elucidated. In this study, we have analyzed 2,398 English-language papers and 6,968 Chinese-language papers published between 1987 and 2017 by using bibliometrics. A steady growth in the number of publications was observed before 2004, followed by an exponential increase between 2004 and 2017. The most common category for publications about Ganoderma was “Pharmacology & Pharmacy,” in which immunomodulation (25.60%) and cancer treatment (21.40%) were the most popular subcategories. Moreover, we have provided an overview of the bioactive components and combinatorial immunomodulatory effects for the use of Ganoderma in the treatment of cancer, including the major pathways of immune cells. Immunomodulatory protein and polysaccharides are the key bioactive factors responsible for cancer immunotherapy, and the NF-κB and MAPK pathways are the most comprehensively investigated major pathways. Our results indicate that Ganoderma has a broad-spectrum application for the treatment of cancer through the regulation of the immune system. This review provides guidance for future research into the role of Ganoderma in cancer immunotherapy. |
format | Online Article Text |
id | pubmed-6209820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62098202018-11-08 Ganoderma: A Cancer Immunotherapy Review Cao, Yu Xu, Xiaowei Liu, Shujing Huang, Linfang Gu, Jian Front Pharmacol Pharmacology Ganoderma is a significant source of natural fungal medicines and has been used for the treatment of various diseases for many years. However, the use of Ganoderma in cancer immunotherapy is poorly elucidated. In this study, we have analyzed 2,398 English-language papers and 6,968 Chinese-language papers published between 1987 and 2017 by using bibliometrics. A steady growth in the number of publications was observed before 2004, followed by an exponential increase between 2004 and 2017. The most common category for publications about Ganoderma was “Pharmacology & Pharmacy,” in which immunomodulation (25.60%) and cancer treatment (21.40%) were the most popular subcategories. Moreover, we have provided an overview of the bioactive components and combinatorial immunomodulatory effects for the use of Ganoderma in the treatment of cancer, including the major pathways of immune cells. Immunomodulatory protein and polysaccharides are the key bioactive factors responsible for cancer immunotherapy, and the NF-κB and MAPK pathways are the most comprehensively investigated major pathways. Our results indicate that Ganoderma has a broad-spectrum application for the treatment of cancer through the regulation of the immune system. This review provides guidance for future research into the role of Ganoderma in cancer immunotherapy. Frontiers Media S.A. 2018-10-25 /pmc/articles/PMC6209820/ /pubmed/30410443 http://dx.doi.org/10.3389/fphar.2018.01217 Text en Copyright © 2018 Cao, Xu, Liu, Huang and Gu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cao, Yu Xu, Xiaowei Liu, Shujing Huang, Linfang Gu, Jian Ganoderma: A Cancer Immunotherapy Review |
title | Ganoderma: A Cancer Immunotherapy Review |
title_full | Ganoderma: A Cancer Immunotherapy Review |
title_fullStr | Ganoderma: A Cancer Immunotherapy Review |
title_full_unstemmed | Ganoderma: A Cancer Immunotherapy Review |
title_short | Ganoderma: A Cancer Immunotherapy Review |
title_sort | ganoderma: a cancer immunotherapy review |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209820/ https://www.ncbi.nlm.nih.gov/pubmed/30410443 http://dx.doi.org/10.3389/fphar.2018.01217 |
work_keys_str_mv | AT caoyu ganodermaacancerimmunotherapyreview AT xuxiaowei ganodermaacancerimmunotherapyreview AT liushujing ganodermaacancerimmunotherapyreview AT huanglinfang ganodermaacancerimmunotherapyreview AT gujian ganodermaacancerimmunotherapyreview |